GlassScriptPhysician profile
Stephanie Jeske
NPI 1194942813
$629.90
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.69 · 2020: $25.24 · 2021: $145 · 2022: $71.21 · 2023: $84.99 · 2024: $139 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.17 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $265.43 | 2020-2024 | |
| Gilead Sciences, INC. | $96.91 | 2021-2023 | Trodelvy |
| Grifols USA, LLC | $86.03 | 2025 | Prolastin-C Liquid |
| Abbvie INC. | $55.62 | 2024-2025 | |
| Array Biopharma INC | $33.86 | 2024 | Mektovi, Lorbrena, Braftovi |
| Tempus Ai, INC | $26.91 | 2024 | |
| Genentech USA, INC. | $22.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.80 | 2019 | |
| Janssen Biotech, INC. | $13.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2025 | Opdivo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Jeske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.